Chesapeake Energy (CHK) Forms $3.76 Double Bottom; 5 Bullish Analysts Covering Fibrocell Science, Inc. (FCSC)

December 7, 2017 - By Hazel Jackson

Among 6 analysts covering Fibrocell Science (NASDAQ:FCSC), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Fibrocell Science had 9 analyst reports since September 28, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, September 26. The company was initiated on Tuesday, December 22 by TH Capital. On Thursday, October 5 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm earned “Buy” rating on Tuesday, December 22 by Roth Capital. The rating was downgraded by Wedbush to “Neutral” on Monday, September 28. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, August 9 report. The firm has “Buy” rating by H.C. Wainwright given on Friday, June 9. See Fibrocell Science, Inc. (NASDAQ:FCSC) latest ratings:

05/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $7.6 Maintain
26/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $7.6 Maintain
11/09/2017 Broker: Canaccord Genuity Rating: Buy New Target: $7.0
09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.7000 Maintain
09/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.7000 Maintain




Chesapeake Energy Corporation (CHK) formed double bottom with $3.50 target or 7.00% below today’s $3.76 share price. Chesapeake Energy Corporation (CHK) has $3.37 billion valuation. The stock decreased 0.27% or $0.01 during the last trading session, reaching $3.76. About 7.77M shares traded. Chesapeake Energy Corporation (NYSE:CHK) has risen 49.74% since December 7, 2016 and is uptrending. It has outperformed by 33.04% the S&P500.

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company has market cap of $10.30 million. The companyÂ’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It currently has negative earnings. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.

The stock decreased 30.03% or $0.3003 during the last trading session, reaching $0.6997. About 1.61M shares traded or 922.90% up from the average. Fibrocell Science, Inc. (NASDAQ:FCSC) has declined 57.80% since December 7, 2016 and is downtrending. It has underperformed by 74.50% the S&P500.

Among 32 analysts covering Chesapeake Energy Corporation (NYSE:CHK), 7 have Buy rating, 7 Sell and 18 Hold. Therefore 22% are positive. Chesapeake Energy Corporation had 85 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Hold” on Tuesday, June 6. The company was maintained on Wednesday, September 13 by Stifel Nicolaus. The firm earned “Neutral” rating on Tuesday, November 17 by Sterne Agee CRT. The stock of Chesapeake Energy Corporation (NYSE:CHK) has “Hold” rating given on Friday, March 11 by Deutsche Bank. The firm has “Sell” rating by ValuEngine given on Monday, May 29. The company was maintained on Wednesday, October 14 by Deutsche Bank. On Monday, September 21 the stock rating was upgraded by Vetr to “Buy”. Deutsche Bank maintained it with “Hold” rating and $6 target in Wednesday, December 9 report. The firm earned “Hold” rating on Thursday, November 10 by Jefferies. As per Tuesday, August 16, the company rating was upgraded by Capital One.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.